Lynparza (Olaparib): The 2027 Generic Opportunity Window
Lynparza, AstraZeneca and Merck's first-in-class oral PARP inhibitor for BRCA-mutated ovarian, breast, prostate, and pancreatic cancers, generated $3.28 billion in global sales in 2025, and no generic version is commercially sold in the United States today. Its core drug-substance and drug-product patent, US 7,449,464, runs to September 8, 2027, with formulation protection extending through December 2029. Leading Indian generic manufacturers are already positioned for commercialization: Natco Pharma, partnered with Alembic Pharmaceuticals, secured tentative FDA approval in July 2026 for generic 100mg and 150mg tablets, alongside pending Paragraph IV filings from Cipla and Zydus Pharmaceuticals.
What we do
We track expirations like this continuously
This is one drug, picked for today's post. A Portfolio Retainer watches an entire portfolio or compound class on an ongoing basis and flags new matching filings as they publish.